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c-Abl, an additional 
tyrosine kinase required 
for T cell development and 
function
T cell receptor (TCR) signaling involves a 
cascade of tyrosine kinase activation. Members 
of three well-characterized kinase families are 
required for this pathway, including a Src family 
kinase (Lck and/or Fyn), a Syk family kinase 
(Zap70), and a Tec family kinase (Itk). Upon 
antigen recognition, these kinases are recruited 
into TCR signaling complexes in a sequential 
manner, leading to the tyrosine phosphorylation 
of downstream signaling molecules, and thereby 
promoting T cell activation. Accordingly, deficien-
cies in each of these kinases cause disrupted 
thymocyte development and defective activation 
of mature T cells.1,2 In this issue of Cell Cycle, 
Silberman et al. show that c-Abl, a tyrosine 
kinase well known for its association with cancer, 
becomes the fourth tyrosine kinase to contribute to 
T cell development and function. 
Previous reports have shown that c-Abl-
deficient mice have impaired lymphocyte 
development, resulting in splenic and thymic 
atrophy, lymphopenia, and increased suscepti-
bility to infection.3,4 However, mice carrying a 
germline deficiency in c-Abl have a broad range 
of abnormalities, including increased neonatal 
lethality; hence, a detailed investigation of the 
T cells in these mice was not feasible. To avoid 
this complication, Silberman et al. used a condi-
tional knockout strategy, where c-Abl could be 
selectively deleted in T cells. With this approach, 
they showed that a T cell-specific c-Abl deficiency 
leads to thymic atrophy and defective periph-
eral T cell activation, confirming the long held 
speculation that c-Abl plays an autonomous role in 
T cell development and activation. Silberman et al. 
carefully studied the thymic atrophy resulting from 
the absence of c-Abl, and analyzed both prolif-
eration and apoptosis of the c-Abl-/- thymocytes. 
Interestingly, they found that the proliferation of 
c-Abl-/- thymocytes was not altered relative to 
wild-type thymocytes; instead increased numbers 
of c-Abl-/- thymocytes, particularly CD4-8+ and 
CD4+8+ cells, showed evidence of undergoing 
apoptosis. Biochemical studies revealed that phos-
phorylation of the p38 MAP-kinase on Thr180/
Tyr182 was consistently higher in c-Abl-/- thymo-
cytes than control cells, likely contributing to the 
enhanced susceptibility of these cells to sponta-
neous apoptosis. 
Silberman et al. also showed that mature 
peripheral T cells lacking c-Abl had a phenotype 
distinct from thymocytes. Specifically, peripheral 
c-Abl-/- T cells were impaired in their ability 
to proliferate in response to mitogenic stimula-
tion. In addition, cell surface receptors that are 
normally upregulated following T cell activation 
were not appropriately induced in the c-Abl-/- 
T cells.  Addition of exogenous IL-2 only partially 
compensated for the impaired expansion of the 
c-Abl-/- T cells following in vitro activation, indi-
cating that the defect in these cells was not simply 
a result of insufficient secretion of IL-2.  This study 
also showed that c-Abl-/- peripheral T cells, like 
the thymocytes from these mice, had defects in 
survival, resulting in enhanced apoptosis of prolif-
erating c-Abl-/- T cells compared to those from 
wild-type mice. 
Finally, Silberman et al. examined whether 
the impaired development and in vitro function of 
c-Abl-/- T cells led to defective T cell responses in 
intact animals. Using a transplantable tumor model, 
these studies revealed that, contrary to control 
mice, mice with c-Abl-/- T cells fail to control tumor 
cell growth. Detailed analysis showed that c-Abl-/- 
T cells were less efficient at killing the tumor cells, 
and further, that the levels of tumor-specific anti-
bodies in the sera of conditional c-Abl-/- mice were 
also reduced relative to controls. Together these 
data support the conclusion that c-Abl is important 
for the optimal function of both CD8+ (tumor cell 
killing) and CD4+ (B cell help) T cells, providing 
a compelling explanation for the inability of these 
mice to reject the transplanted tumor. 
When the bcr gene rearranges adjacent to the 
abl gene due to chromosomal translocation, the 
fusion protein Bcr-Abl is generated.5 This fusion 
protein has constitutive Abl tyrosine kinase activity 
and is responsible for 95% of patients with CML 
and 25% of adult patients with ALL.6-8 However, 
recent studies have shown that c-Abl is not only 
oncogenic when fused to BCR, but also when its 
expression level or activity is upregulated. For 
example, increased c-Abl expression was detected 
in some T cell lymphomas due to decreased 
levels of microRNA-203; this microRNA normally 
targets c-Abl mRNA, thereby down-regulating 
c-Abl protein levels.9 The work of Silberman et al. 
provides a better understanding of the function of 
c-Abl in T cells, and thus provides insight into the 
potential mechanisms by which dysregulated c-Abl 
activity can contribute to T lymphoma formation.
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